Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2031

Conditions
Biliary Tract CancerCholangiocarcinomaBiliary Tract Neoplasms
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Udai Kammula

OTHER